On June 26, 2026, Chancellor Kathaleen St. J. McCormick of the Delaware Court of Chancery dismissed in full a six-count, $700 million derivative action brought by a minority stockholder challenging an investor's consolidation of control over a life-sciences company. The decision in Rostov v. Alcon Research, LLC, C.A. No. 2025-0648-KSJM, provides important guidance on the limits of fiduciary-duty claims in the context of corporate control contests, director inaction, and preferred-stock governance disputes. 

The Dispute

The case arose from a multi-year battle between rival investors in Aurion Biotech, Inc., a company developing corneal endothelial cell therapy. Alcon Research, LLC held Series C preferred stock, board designation rights, and consent rights over major corporate actions. A rival faction pushed toward an IPO that would have converted Alcon's preferred shares and stripped its protective rights. 

After an independent special committee unanimously voted to postpone the IPO in February 2025, Alcon acquired additional shares to become the controlling stockholder, reshaped the board, and dissolved the special committee. Former CFO and co-founder David Rostov then filed a derivative action alleging that Alcon, certain directors, and other investors wrongfully derailed an IPO he valued at hundreds of millions of dollars. 

The Ruling

Chancellor McCormick dismissed all six counts at the pleading stage, finding that the complaint's central theory was fatally undermined by its own timeline: the independent special committee had already postponed the IPO before Alcon became a controller and before any of the challenged conduct occurred. 

The Court held that the plaintiff could not recast a business disagreement as fiduciary misconduct and could not substitute his preferred corporate strategy for the board's judgment. The claims against the directors failed because the plaintiff relied on impermissible "group pleading" against directors protected by an exculpatory charter provision rather than alleging individualized bad faith. The claim that a director breached his duty by resigning was distinguished from the extreme circumstances of In re Puda Coal and dismissed. The contractual right-of-first-refusal claim collapsed because the relevant schedule was blank and the plain language of the agreement—under the last-antecedent rule—excluded preferred stock from the operative provision. 

Key Takeaways

• Timeline matters. A complaint that alleges harm from challenged conduct but concedes on its face that the harm predated the conduct will fail at the pleading stage.
• Business disagreement is not fiduciary misconduct. Delaware law does not permit a minority stockholder's preferred corporate strategy to override the board's business judgment.
• Group pleading will not defeat exculpation. Where directors are protected by an exculpatory charter provision, plaintiffs must plead individualized bad faith—blanket allegations against the board as a whole are insufficient.
• Director resignations are generally permissible. Absent extreme circumstances akin to those in Puda Coal—where directors resigned to leave a company in the hands of a suspected wrongdoer—the act of resigning does not give rise to a fiduciary breach.
• Contractual provisions live and die by their plain language. Courts will enforce the text of an agreement as written, including applying the last-antecedent rule and declining to rewrite blank schedules.
• Strategic investors can protect their position. The ruling affirms that preferred stockholders and board designees may take commercially motivated positions—including opposing transactions that would dilute their rights—without crossing the line into fiduciary misconduct.